The research demonstrates a pathogenic role for CELF1 in contributing to the Cx43 mRNA degradation during heart failure and was published in Circulation Research.
Many drugs are conjugated with polyethylene glycol (PEG) to increase their solubility, extension of circulation half-lives and reduction in immunogenicity. However, the presence of anti-PEG antibodies in some patients has been shown to affect the therapeutic efficacy and safety of PEGylated drugs.
A team led by Dr. Steve Roffler (IBMS) and Dr. Tian-Lu Cheng (KMU) developed bispecific antibodies that can effectively target nanomedicines for safe and effective treatment of triple-negative breast cancer.
Congratulation to Dr. Carmay Lim、Dr. Chih-Cheng Chen and Dr.Shih Chieh Hung for receiving the MOST Outstanding Research Award.
Based on the research activities, our principle investigators can be divided into 6 areas: Epidemiology & Genetics Division, Neuroscience Division, Cardiovascular Research Division, Infectious Disease & Immunology Division, Cancer Division, and Structural Biology Division.